[go: up one dir, main page]

US20060128964A1 - Method for preparing 2- (2-pyridylmethylsulphinyl) benzimidazoles - Google Patents

Method for preparing 2- (2-pyridylmethylsulphinyl) benzimidazoles Download PDF

Info

Publication number
US20060128964A1
US20060128964A1 US11/115,160 US11516005A US2006128964A1 US 20060128964 A1 US20060128964 A1 US 20060128964A1 US 11516005 A US11516005 A US 11516005A US 2006128964 A1 US2006128964 A1 US 2006128964A1
Authority
US
United States
Prior art keywords
solvent
alkyl
catalyst
oxidation reaction
halogenated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/115,160
Other versions
US7064213B1 (en
Inventor
Chih-Hung Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industrial Technology Research Institute ITRI
Syn-Tech Chem and Pharm Co Ltd
Original Assignee
Industrial Technology Research Institute ITRI
Syn-Tech Chem and Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industrial Technology Research Institute ITRI, Syn-Tech Chem and Pharm Co Ltd filed Critical Industrial Technology Research Institute ITRI
Assigned to SYN-TECH CHEM & PHARM CO., LTD., INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE reassignment SYN-TECH CHEM & PHARM CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEN, CHIH-HUNG
Publication of US20060128964A1 publication Critical patent/US20060128964A1/en
Application granted granted Critical
Publication of US7064213B1 publication Critical patent/US7064213B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention provides a method for preparing an antiulcer agent, 2-(2-pyridylmethylsulphinyl)benzimidazoles, such as Omeprazole, Lansoprazole and Pantoprazole, and particularly to a catalyst for the oxidation reaction in the preparation method.
  • a method for preparing Lansoprazole comprises oxidizing 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylthio]-1 H -benzimida zole using H 2 O 2 in the presence of a V 2 O 5 catalyst.
  • Omeprazole, Lansoprazole, and Pantoprazole include m-chloroperbenzoic acid (MCPBA) (U.S. Pat. No. 4,628,098, U.S. Pat. No. 5,386,032), sodium perborate tetrahydrate (NaBO 3 .4H 2 O)/H 2 O 2 [WO99/02521 (1999)], ammonium molybdate ((NH 4 ) 2 MoO 4 )/H 2 O 2 (ES Patent 2,036,948 (1993)).
  • MCPBA m-chloroperbenzoic acid
  • NaBO 3 .4H 2 O sodium perborate tetrahydrate
  • H 2 O 2 [WO99/02521 (1999)
  • ammonium molybdate (NH 4 ) 2 MoO 4 )/H 2 O 2 (ES Patent 2,036,948 (1993)).
  • the inventor of the present invention used V 2 O 5 as an oxidation catalyst and used H 2 O 2 for the oxidation reaction of Lansoprazole and Omeprazole.
  • the reaction ratio can reach above 90% and the oxidation by-products can be controlled to be within 1-2%, the reaction products are liable to become black and cannot be discolored. Therefore, the method is rather difficult in quality control.
  • MCPBA is a conventional catalyst commonly used in the oxidation production of Omeprazole, Lansoprazole, and Pantoprazole, etc.
  • the reaction temperature is ⁇ 20° C. ⁇ 60° C., and MCPBA is expensive.
  • the present invention discloses a method for preparing 2-(2-pyridylmethylsulphinyl)benzimidazole having the following formula [A], which comprises undergoing an oxidation reaction of an intermediate having the following formula [B] in a solvent and in the presence of a catalyst and an oxidant to form the compound [A]: wherein R 1 in [A] and [B] is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, or halogenated C1-C6 alkoxy; R 2 and R 3 independently are hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, or halogenated C1-C6 alkoxy; and R 4 is hydrogen, halogen, C1-C6 alkyl, or halogenated C1-C6 alkyl; characterized in that said catalyst is acetyl acetonate
  • said oxidant is H 2 O 2 , tert-butylhydroperoxide, or Cumene hydroperoxide.
  • said solvent is C1-C6 alcohol, chlorinated C1-C4 alkane, or ethyl acetate. More preferably, said solvent is methanol, ethanol, iso-propanol, n-butanol, or iso-butanol. More preferably, said solvent is dichloromethane, dichloroethane, or ethyl acetate.
  • said oxidation reaction is carried out in a homogeneous phase solvent or a two-phase solvent.
  • said oxidation reaction is carried out in the two-phase solvent, and an interphase transfer catalyst is added to the two-phase solvent, so that the oxidation reaction is carried out under the presence of said interphase transfer catalyst, wherein said interphase transfer catalyst is selected from the group consisting of quaternary ammonium salt, quaternary phosphate salt, polyether, and crown ether.
  • said oxidation reaction is carried out in a temperature of ⁇ 15 ⁇ 30° C.
  • a weight ratio of said solvent to said intermediate [B] is 2:1 to 20:1 in the oxidation reaction.
  • a mole ratio of said oxidant to said intermediate [B] is 1:1 to 5:1 in the oxidation reaction.
  • a weight ratio of said catalyst to said intermediate [B] is 3% to 20% in the oxidation reaction.
  • said compound [A] is Lansoprazole.
  • said compound [A] is Omeprazole.
  • said compound [A] is Pantoprazole.
  • the present invention adopts an organic composite catalyst, e.g. molybdenyl acetyl acetone (also named as acetylacetonate of molybdenium) (hereinafter abbreviated as Mo(acac) 2 ), together with an oxidant, for the oxidation reaction of the precursors of benzimidazole compounds, such as Omeprazole, Lansoprazole, and Pantoprazole.
  • the reaction conditions are mild without severe temperature conditions.
  • a Mo-series catalyst is less toxic than a vanadium catalyst.
  • the reaction produces a rather small amount of the by-products I and II (1-2%).
  • a preparation method according to the present invention is far superior in comparison to the conventional preparation methods.
  • the method for preparing a thio-containing antiulcer agent, such as Omeprazole, Lansoprazole and Pantoprazole, according to the present invention is improved over the conventional methods and applicable for mass production.
  • a method according to the present invention comprises separately preparing precursor intermediates 1, 2, 3 of Omeprazole, Lansoprazole, and Pantoprazole; preparing a suitable solvent such as methanol, ethanol, and propanol, or a two-phase solvent of water and ethyl acetate, dichloromethane, dichloroethane, or tetrahydrofuran, wherein an interphase transfer catalyst (e.g.
  • quaternary ammonium salt polyether, quaternary phosphate salt, or crown ether (preferably polyether, or crown ether)) is added to the two-phase solvent; adding the intermediate and a catalyst Mo(acac) 2 into the solvent; and finally adding batchwise or in one lot an oxidant into the resulting mixture to undergo an oxidation reaction at 0-30° C.
  • a suitable oxidant is selected from the group consisting of H 2 O 2 , sodium percarbonate, tert-butylhydroperoxide (abbreviated as TBHP), cumene hydroperoxide, and Fremyl's salt, wherein H 2 O 2 and TBHP are preferable.
  • Omeprazole precursor 2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylthio]-5-methoxy-1H-benzimidazole, 0.09 g of Mo(acac) 2 oxidation catalyst were dissolved in 20 ml of methanol by stirring. The temperature of the resulting solution was reduced to 0-5° C., followed by adding 1.17 g of 35% H 2 O 2 aqueous solution. The reaction was carried out for about two hours, and then 60 ml of water was added, and the reaction was continued for another one hour while stirring. Finally, the precipitate formed was filtered, water washed, and dried to obtain Omeprazole with a yield of about 91-92% (HPLC purity >98%).
  • Pantoprazole precursor 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methylthio]-1 H -benzimidazole, 0.095 g of Mo(acac) 2 oxidation catalyst were dissolved in 20 ml of methanol. The temperature of the solution was reduced to 0-5° C. To the solution 1.17 g of 35% H 2 O 2 aqueous solution was added and the reaction was carried out for about two hours, and then 60 ml of water was added, and the reaction was continued for another one hour while stirring. Finally, the precipitate formed was filtered, water washed, and dried to obtain Pantoprazole with a yield of about 60% (HPLC purity >98%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a method for preparing an antiulcer agent, 2-(2-pyridylmethylsulphinyl)benzimidazoles, such as Omeprazole, Lansoprazole and Pantoprazole, which includes oxidizing an intermediate having a linkage of methylthio group (—CH2S—) to methylsulfinyl (—CH2S(O)—) in the presence of an oxidation catalyst of acetyl acetonate of molybdenium (II) [(CH3C(O)CH2C(O)CH2)2Mo].

Description

    FIELD OF THE INVENTION
  • The present invention provides a method for preparing an antiulcer agent, 2-(2-pyridylmethylsulphinyl)benzimidazoles, such as Omeprazole, Lansoprazole and Pantoprazole, and particularly to a catalyst for the oxidation reaction in the preparation method.
    • BACKGROUND OF THE INVENTION
  • Many patents have disclosed a series of 2-(2-pyridylmethylsulphinyl)benzimidazoles as excellent agents for inhibiting the secretion of gastric acid, for example 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole (generic name: Omeprazole), 2-[[3-methy-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]-1H-benzimidazole (generic name: Lansoprazole), and 5-Difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl-methylsulfinyl)-1H-benzimidazole] (generic name: Pantoprazole). One common technical feature for the preparation of these benzimidazole compounds includes that individual precursors 1, 2, or 3 need to undergo similar oxidation reactions to form sulfinyl final products. According to European Patent EP0302720, a method for preparing Lansoprazole comprises oxidizing 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylthio]-1H-benzimida zole using H2O2 in the presence of a V2O5 catalyst. Other than the above-mentioned V2O5/H2O2 method, other oxidation methods for preparing Omeprazole, Lansoprazole, and Pantoprazole include m-chloroperbenzoic acid (MCPBA) (U.S. Pat. No. 4,628,098, U.S. Pat. No. 5,386,032), sodium perborate tetrahydrate (NaBO3.4H2O)/H2O2 [WO99/02521 (1999)], ammonium molybdate ((NH4)2MoO4)/H2O2 (ES Patent 2,036,948 (1993)).
    Figure US20060128964A1-20060615-C00001
  • According to prior art, the inventor of the present invention used V2O5 as an oxidation catalyst and used H2O2 for the oxidation reaction of Lansoprazole and Omeprazole. Although the reaction ratio can reach above 90% and the oxidation by-products can be controlled to be within 1-2%, the reaction products are liable to become black and cannot be discolored. Therefore, the method is rather difficult in quality control. MCPBA is a conventional catalyst commonly used in the oxidation production of Omeprazole, Lansoprazole, and Pantoprazole, etc. However, when MCPBA is used as an oxidant, the reaction temperature is −20° C.˜−60° C., and MCPBA is expensive. Under consideration of the low-temperature reaction condition and the production cost, such a method has substantial difficulties in mass production. The inventor of the present invention also conducted investigations in using NaBO3.4H2O/H2O2 for the oxidation reaction of Lansoprazole, wherein, even though the reaction ratio can reach around 90%, excessive amount (5%-10%) of oxidation by-products having the following formula I and II are formed:
    Figure US20060128964A1-20060615-C00002
    The physical properties of the by-products I and II are rather close to the physical properties of the desired product. Thus, the desired product, after crystallization purification of the reaction product mixture, are rather difficult to be separated from the by-products I and II. If further elaborate purifications are performed, the yield is liable to drop dramatically.
  • When (NH4)2MoO4)/H2O2 is used as an oxidant rather than NaBO3.4H2O/H2O2, more oxidation by-products I and II (8˜20%) are produced, and the total yield is about 75%. Thus, such a process is not industrially feasible.
  • It can be understood from the above that the industry is still looking for a method for commercially mass production of 2-(2-pyridylmethylsulphinyl)benzimidazoles, such as Omeprazole, Lansoprazole and Pantoprazole, with mild reaction conditions, capable of effectively inhibiting excessive formation of the oxidation by-products I and II, and simple in purification of the desired products.
    • SUMMARY OF THE INVENTION
  • The present invention discloses a method for preparing 2-(2-pyridylmethylsulphinyl)benzimidazole having the following formula [A], which comprises undergoing an oxidation reaction of an intermediate having the following formula [B] in a solvent and in the presence of a catalyst and an oxidant to form the compound [A]:
    Figure US20060128964A1-20060615-C00003
    wherein R1 in [A] and [B] is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, or halogenated C1-C6 alkoxy; R2 and R3 independently are hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, or halogenated C1-C6 alkoxy; and R4 is hydrogen, halogen, C1-C6 alkyl, or halogenated C1-C6 alkyl; characterized in that said catalyst is acetyl acetonate of molybdenium (II), titanium, cobalt, or copper, and preferably acetonate of molybdenium (II).
  • Preferably, said oxidant is H2O2, tert-butylhydroperoxide, or Cumene hydroperoxide.
  • Preferably, in said solvent is C1-C6 alcohol, chlorinated C1-C4 alkane, or ethyl acetate. More preferably, said solvent is methanol, ethanol, iso-propanol, n-butanol, or iso-butanol. More preferably, said solvent is dichloromethane, dichloroethane, or ethyl acetate.
  • Preferably, said oxidation reaction is carried out in a homogeneous phase solvent or a two-phase solvent.
  • Preferably, said oxidation reaction is carried out in the two-phase solvent, and an interphase transfer catalyst is added to the two-phase solvent, so that the oxidation reaction is carried out under the presence of said interphase transfer catalyst, wherein said interphase transfer catalyst is selected from the group consisting of quaternary ammonium salt, quaternary phosphate salt, polyether, and crown ether.
  • Preferably, said oxidation reaction is carried out in a temperature of −15˜30° C.
  • Preferably, a weight ratio of said solvent to said intermediate [B] is 2:1 to 20:1 in the oxidation reaction.
  • Preferably, a mole ratio of said oxidant to said intermediate [B] is 1:1 to 5:1 in the oxidation reaction.
  • Preferably, a weight ratio of said catalyst to said intermediate [B] is 3% to 20% in the oxidation reaction.
  • Preferably, said compound [A] is Lansoprazole.
  • Preferably, said compound [A] is Omeprazole.
  • Preferably, said compound [A] is Pantoprazole.
  • The present invention adopts an organic composite catalyst, e.g. molybdenyl acetyl acetone (also named as acetylacetonate of molybdenium) (hereinafter abbreviated as Mo(acac)2), together with an oxidant, for the oxidation reaction of the precursors of benzimidazole compounds, such as Omeprazole, Lansoprazole, and Pantoprazole. According to the present invention, the reaction conditions are mild without severe temperature conditions. Furthermore, a Mo-series catalyst is less toxic than a vanadium catalyst. Most importantly, the reaction produces a rather small amount of the by-products I and II (1-2%). Accordingly, a preparation method according to the present invention is far superior in comparison to the conventional preparation methods. Thus, the method for preparing a thio-containing antiulcer agent, such as Omeprazole, Lansoprazole and Pantoprazole, according to the present invention is improved over the conventional methods and applicable for mass production.
    • DETAILED DESCRIPTION OF THE INVENTION
  • A method according to the present invention comprises separately preparing precursor intermediates 1, 2, 3 of Omeprazole, Lansoprazole, and Pantoprazole; preparing a suitable solvent such as methanol, ethanol, and propanol, or a two-phase solvent of water and ethyl acetate, dichloromethane, dichloroethane, or tetrahydrofuran, wherein an interphase transfer catalyst (e.g. quaternary ammonium salt, polyether, quaternary phosphate salt, or crown ether (preferably polyether, or crown ether)) is added to the two-phase solvent; adding the intermediate and a catalyst Mo(acac)2 into the solvent; and finally adding batchwise or in one lot an oxidant into the resulting mixture to undergo an oxidation reaction at 0-30° C. A suitable oxidant is selected from the group consisting of H2O2, sodium percarbonate, tert-butylhydroperoxide (abbreviated as TBHP), cumene hydroperoxide, and Fremyl's salt, wherein H2O2 and TBHP are preferable.
    • EXAMPLE 1
  • 2.68 g of 2-chloromethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine.HCl, 1.376 g of 2-mercaptobenzimidazole, and 0.134 g of benzyl triethyl ammonium chloride as an interphase transfer catalyst were mixed in 24 ml of dichloromethane. 0.9534 g of NaOH (40%)/12 ml water mixture solution was dripped into the above mixture while stirring. The temperature of the resulting solution was raised to 40° C. for about 2 hours. Then, dichloromethane was removed from the mixture under a reduced pressure. The solid obtained was stirred with 50 ml of water, and filtered to obtain 3.28 g of solid Lansoprazole precursor: 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylthio]-1H-benzimidazole. At room temperature, 3.28 g of the above precursor, 0.1625 g of polyethylene glycol-400 as an interphase transfer catalyst, and 0.3936 g of Mo(acac)2 as an oxidation catalyst were mixed in 45 ml of isopropanol (abbreviated as IPA). To the resulting mixture 3.06 g of 35% H2O2 aqueous solution was added in 5-10 minutes. The reaction was carried out for about one hour, and then 60 ml of water was added, and the reaction was continued for another one hour while stirring. Finally, the precipitate formed was filtered, water washed, and dried to obtain Lansoprazole with a yield of about 88% (HPLC purity >98%).
    • EXAMPLE 2
  • At room temperature, 1.307 g of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylthio]-1H-benzimidazole, 0.059 g of tetrabutyl ammonium bromide as an interphase transfer catalyst, and 0.157 g of Mo(acac)2 oxidation catalyst were mixed in 15 ml of IPA. Next, 1.36 g of TBHP (70% aqueous solution) was added into the mixture in about 5-10 minutes. The reaction was carried out for about 30 hours, and then 60 ml of water was added, and the reaction was continued for another one hour while stirring. Finally, the precipitate formed was filtered, water washed, and dried to obtain Lansoprazole with a yield of about 37% (HPLC purity >96%).
    • EXAMPLE 3
  • 3 g of Omeprazole precursor: 2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylthio]-5-methoxy-1H-benzimidazole, 0.09 g of Mo(acac)2 oxidation catalyst were dissolved in 20 ml of methanol by stirring. The temperature of the resulting solution was reduced to 0-5° C., followed by adding 1.17 g of 35% H2O2 aqueous solution. The reaction was carried out for about two hours, and then 60 ml of water was added, and the reaction was continued for another one hour while stirring. Finally, the precipitate formed was filtered, water washed, and dried to obtain Omeprazole with a yield of about 91-92% (HPLC purity >98%).
    • EXAMPLE 4
  • 3.17 g of Pantoprazole precursor: 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methylthio]-1H-benzimidazole, 0.095 g of Mo(acac)2 oxidation catalyst were dissolved in 20 ml of methanol. The temperature of the solution was reduced to 0-5° C. To the solution 1.17 g of 35% H2O2 aqueous solution was added and the reaction was carried out for about two hours, and then 60 ml of water was added, and the reaction was continued for another one hour while stirring. Finally, the precipitate formed was filtered, water washed, and dried to obtain Pantoprazole with a yield of about 60% (HPLC purity >98%).

Claims (17)

1. A method for preparing 2-(2-pyridylmethylsulphinyl) benzimidazole having the following formula [A], which comprises undergoing an oxidation reaction of an intermediate having the following formula [B] in a solvent and in the presence of a catalyst and an oxidant to form the compound [A]:
Figure US20060128964A1-20060615-C00004
wherein R1 in [A] and [B] is hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, or halogenated C1-C6 alkoxy; R2 and R3 independently are hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkyl, or halogenated C1-C6 alkoxy; and R4 is hydrogen, C1-C6 alkyl, or halogenated C1-C6 alkyl; characterized in that said catalyst is acetyl acetonate of molybdenium (II).
2. The method as claimed in claim 1, wherein said oxidant is H2O2, tert-butylhydroperoxide, or Cumene hydroperoxide.
3. The method as claimed in claim 1, wherein said solvent is C1-C6 alcohol, chlorinated C1-C4 alkane, or ethyl acetate.
4. The method as claimed in claim 3, wherein said solvent is methanol, ethanol, iso-propanol, n-butanol, or iso-butanol.
5. The method as claimed in claim 3, wherein said solvent is dichloromethane, dichloroethane, or ethyl acetate.
6. The method as claimed in claim 1, wherein said oxidation reaction is carried out in a homogeneous phase solvent or a two-phase solvent.
7. The method as claimed in claim 6, wherein said oxidation reaction is carried out in the two-phase solvent, and an interphase transfer catalyst is added to the two-phase solvent, so that the oxidation reaction is carried out under the presence of said interphase transfer catalyst, wherein said interphase transfer catalyst is selected from the group consisting of quaternary ammonium salt, quaternary phosphate salt, polyether, and crown ether.
8. The method as claimed in claim 1, wherein said oxidation reaction is carried out in a temperature of −15˜30° C.
9. The method as claimed in claim 1, wherein a weight ratio of said solvent to said intermediate [B] is 2:1 to 20:1.
10. The method as claimed in claim 1, wherein a mole ratio of said oxidant to said intermediate [B] is 1:1 to 5:1.
11. The method as claimed in claim 1, wherein a weight ratio of said catalyst to said intermediate [B] is 3% to 20%.
12. The method as claimed in claim 1, wherein said compound [A] is 2-[[3-methy-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]methylsulfinyl]-1H-benzimidazole.
13. The method as claimed in claim 1, wherein said compound [A] is 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl]-1H-benzimidazole.
14. The method as claimed in claim 1, wherein said compound [A] is 5-Difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl-methylsulfinyl)-1H-benzimidazole].
15. (canceled)
16. The method as claimed in claim 7, wherein said interphase transfer catalyst is polyether.
17. The method as claimed in claim 16, wherein said, polyether is polyethylne glycol.
US11/115,160 2004-12-10 2005-04-27 Method for preparing 2- (2-pyridylmethylsulphinyl) benzimidazoles Expired - Fee Related US7064213B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TW93138386 2004-12-10
TW093138386A TW200619198A (en) 2004-12-10 2004-12-10 Method for preparing 2-(2-pyridylmethylsulphinyl)benzimidazoles

Publications (2)

Publication Number Publication Date
US20060128964A1 true US20060128964A1 (en) 2006-06-15
US7064213B1 US7064213B1 (en) 2006-06-20

Family

ID=36584958

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/115,160 Expired - Fee Related US7064213B1 (en) 2004-12-10 2005-04-27 Method for preparing 2- (2-pyridylmethylsulphinyl) benzimidazoles

Country Status (2)

Country Link
US (1) US7064213B1 (en)
TW (1) TW200619198A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009066309A3 (en) * 2007-07-12 2010-01-07 Cadila Healthcare Limited Process for preparation of omeprazole

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615913A2 (en) * 2003-06-10 2006-01-18 Teva Pharmaceutical Industries Limited Process for preparing 2-(pyridinyl)methyl sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
US20040138466A1 (en) * 2001-02-02 2004-07-15 Ilya Avrutov Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063705B1 (en) * 1993-06-14 1995-07-16 S A L V A T Lab Sa INTERMEDIATE FOR THE SYNTHESIS OF LANSOPRAZOLE AND ITS PROCEDURE FOR OBTAINING.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
US20040138466A1 (en) * 2001-02-02 2004-07-15 Ilya Avrutov Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009066309A3 (en) * 2007-07-12 2010-01-07 Cadila Healthcare Limited Process for preparation of omeprazole

Also Published As

Publication number Publication date
US7064213B1 (en) 2006-06-20
TW200619198A (en) 2006-06-16

Similar Documents

Publication Publication Date Title
KR101522865B1 (en) Process for the preparation of form a of esomeprazole magnesium dihydrate
EP1409478B1 (en) Improved process for preparing benzimidazole-type compounds
US20080091024A1 (en) Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles
US6603009B2 (en) Method for oxidizing a thioether group into a sulfoxide group
US7105681B2 (en) Process for the preparation of sulphinyl derivatives by oxidation of the corresponding sulfides
KR20000070069A (en) New Process
JP2003527370A5 (en)
US7531666B2 (en) Method for preparing 2-(2-pyridinylmethylsulfinyl) benzimidazoles
US7064213B1 (en) Method for preparing 2- (2-pyridylmethylsulphinyl) benzimidazoles
US8691995B2 (en) Process
US20090076277A1 (en) Process for the preparation of pyridine-methylsulfinyl compounds
AU2006274036B2 (en) Isotopically substituted proton pump inhibitors
US20040138466A1 (en) Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles
US20070225500A1 (en) Process for the Preparation of Pyridin-2-Ylmethylsulphinyl-1H-Benzimidazol Compounds
KR100771655B1 (en) Labeprazole and its preparation method
KR20020026016A (en) Preparation of sulfinyl compounds using a metal catalyst
AU2002240242A1 (en) Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles

Legal Events

Date Code Title Description
AS Assignment

Owner name: SYN-TECH CHEM & PHARM CO., LTD., TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEN, CHIH-HUNG;REEL/FRAME:016514/0934

Effective date: 20050412

Owner name: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEN, CHIH-HUNG;REEL/FRAME:016514/0934

Effective date: 20050412

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.)

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.)

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20180620